Johan Michiels

Research output

Research output per year 1995 2012 2013 2016 2018 2021 2022 2023

• 38 A1: Web of Science-article
• 2 Conference abstract in journal
• 2 Letter

Research output per year

Research output per year

Search results

• 2023

  Validation of a reporter cell line for flavivirus inhibition assays

  Rezende, T. M. T., Macera, G., Heyndrickx, L., Michiels, J., Coppens, S., Thibaut, H. J., Dallmeier, K., Van Esbroeck, M., Neyts, J., Ariën, K. K. & Bartholomeeusen, K., 2023, (E-pub ahead of print) In: Microbiology Spectrum. 10 p., e0502722.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review
• 2022

  A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell mediated immunity

  McCafferty, S., Haque, A. A., Vandierendonck, A., Weidensee, B., Plovyt, M., Stuchlíková, M., François, N., Valembois, S., Heyndrickx, L., Michiels, J., Ariën, K. K., Vandekerckhove, L., Abdelnabi, R., Foo, C. S., Neyts, J., Sahu, I. & Sanders, N. N., 2022, In: Molecular Therapy. 30, 9, p. 2968-2983 16 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • SARS Virus 100%
  • Humoral Immunity 70%
  • Cellular Immunity 64%
  • Vaccines 50%
  • RNA 46%

• Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

  Canti, L., Ariën, K. K., Desombere, I., Humblet-Baron, S., Pannus, P., Heyndrickx, L., Henry, A., Servais, S., Willems, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Goossens, M. E., Beguin, Y., Marchant, A. & Baron, F., 2022, In: Cancer Cell. 40, 4, p. 335-337 3 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

• Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium

  ITM Monkeypox Study Group, 2022, In: Nature Medicine. 28, 11, p. 2288-2292 5 p., 1081.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Monkeypox virus 100%
  • Sexual Health 69%
  • Belgium 68%
  • Virus Diseases 43%
  • Disease Outbreaks 26%

• Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022

  ITM Monkeypox Study Group, 2022, In: Eurosurveillance. 27, 48, 6 p., 3.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

• Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

  Ariën, K. K., Heyndrickx, L., Michiels, J., Vereecken, K., Van Lent, K., Coppens, S., Willems, B., Pannus, P., Martens, G. A., Van Esbroeck, M., Goossens, M. E., Marchant, A., Bartholomeeusen, K. & Desombere, I., 2022, In: Vaccines. 7, 1, 3 p., 35.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • SARS Virus 100%
  • Neutralizing Antibodies 67%
  • Vaccines 50%
  • Infection 32%
  12 Downloads (Pure)
• 2021

  A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity

  Smet, A., Breugelmans, T., Michiels, J., Lamote, K., Arras, W., De Man, J. G., Heyndrickx, L., Hauner, A., Huizing, M., Malhotra-Kumar, S., Lammens, M., Hotterbeekx, A., Kumar-Singh, S., Verstraeten, A., Loeys, B., Verhoeven, V., Jacobs, R., Dams, K., Coenen, S., Ariën, K. K. & 2 others, Jorens, P. G. & De Winter, B. Y., 2021, In: JCI insight. 6, 19

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Mucins 100%
  • Messenger RNA 52%
  • SARS Virus 24%
  • Mucus 17%
  • baricitinib 16%

• Dynamics of the magnitude, breadth and depth of the antibody response at epitope level following dengue infection

  Falconi-Agapito, F., Kerkhof, K., Merino, X., Michiels, J., Van Esbroeck, M., Bartholomeeusen, K., Talledo, M. & Ariën, K. K., 2021, In: Frontiers in Immunology. 12, 21 p., 686691.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File
  11 Downloads (Pure)

• Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay

  Mariën, J., Ceulemans, A., Michiels, J., Heyndrickx, L., Kerkhof, K., Foque, N., Widdowson, M-A., Mortgat, L., Duysburgh, E., Desombere, I., Jansens, H., Van Esbroeck, M. & Ariën, K. K., 2021, In: Journal of Virological Methods. 288, 6 p., 114025.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Coronavirus nucleocapsid protein 100%
  • Coronavirus Spike Glycoproteins 94%
  • Severe Acute Respiratory Syndrome 72%
  • Coronavirus 70%
  • Nucleocapsid 49%

• Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

  Mariën, J., Michiels, J., Heyndrickx, L., Nkuba-Ndaye, A., Ceulemans, A., Bartholomeeusen, K., Madinga, J., Mbala-Kingebeni, P., Vanlerberghe, V., Ahuka-Mundeke, S., Wang, L-F. & Ariën, K. K., 2021, In: Journal of Virological Methods. 297, 114228.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • SARS Virus 100%
  • Neutralization Tests 88%
  • Neutralizing Antibodies 67%
  • Viruses 45%
  • Vaccines 33%

• Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes

  Pannus, P., Neven, K. Y., De Craeye, S., Heyndrickx, L., Vande Kerckhove, S., Georges, D., Michiels, J., Francotte, A., Van Den Bulcke, M., Zrein, M., Van Gucht, S., Schmickler, M-N., Verbrugghe, M., Matagne, A., Thomas, I., Dierick, K., Weiner, J. A., Ackerman, M. E., Goriely, S., Goossens, M. E. & 3 others, Ariën, K. K., Desombere, I. & Marchant, A., 2021, (E-pub ahead of print) In: Clinical Infectious Diseases. 10 p., ciab998.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • SARS Virus 100%
  • Nursing Homes 69%
  • Antibody Formation 60%
  • Vaccination 54%
  • Messenger RNA 38%

• Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

  Canti, L., Humblet-Baron, S., Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., Servais, S., Willems, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A. & Baron, F., 2021, In: Journal of Hematology & Oncology. 14, 1, 12 p., 174.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review
• 2020

  A new genetic variant of dengue serotype 2 virus circulating in the Peruvian Amazon

  Falconi-Agapito, F., Selhorst, P., Merino, X., Torres, F., Michiels, J., Fernandez, C., Talledo, M. & Ariën, K. K., 2020, In: International Journal of Infectious Diseases. 96, p. 136-138 3 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Peru 100%
  • Asian Americans 96%
  • Dengue Virus 93%
  • Dengue 89%
  • Serogroup 71%
  2 Downloads (Pure)

• Two distinct lineages of chikungunya virus cocirculated in Aruba during the 2014-2015 epidemic

  Phadungsombat, J., Tuekprakhon, A., Cnops, L., Michiels, J., van den Berg, R., Nakayama, E. E., Shioda, T., Ariën, K. K. & Huits, R., 2020, In: Infection, Genetics and Evolution. 78, 7 p., 104129.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Aruba 100%
  • chikungunya 79%
  • Chikungunya virus 76%
  • virus 48%
  • Epidemics 43%
  32 Downloads (Pure)
• 2019

  Challenges in diagnosing Zika-experiences from a reference laboratory in a non-endemic setting

  Van den Bossche, D., Michiels, J., Cnops, L., Foque, N., Meersman, K., Huits, R., Ariën, K. K. & Van Esbroeck, M., 2019, In: European Journal of Clinical Microbiology and Infectious Diseases. 38, 4, p. 771-778 8 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Zika Virus 100%
  • Immunoglobulin M 77%
  • Centers for Disease Control and Prevention (U.S.) 45%
  • False Positive Reactions 43%
  • Neutralization Tests 38%
• 2018

  Broad-spectrum monoclonal antibodies against chikungunya virus structural proteins: promising candidates for antibody-based rapid diagnostic test development

  Tuekprakhon, A., Puiprom, O., Sasaki, T., Michiels, J., Bartholomeeusen, K., Nakayama, E. E., Meno, M. K., Phadungsombat, J., Huits, R., Ariën, K. K., Luplertlop, N., Shioda, T. & Leaungwutiwong, P., 2018, In: PLoS ONE. 13, 12, 30 p., e0208851.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Chikungunya virus 100%
  • Viral Structural Proteins 96%
  • Routine Diagnostic Tests 66%
  • Monoclonal Antibodies 51%
  • Antibodies 38%
  5 Downloads (Pure)

• Can Zika virus antibodies cross-protect against dengue virus?

  Ariën, K. K., Michiels, J., Foqué, N., Heyndrickx, L. & Van Esbroeck, M., 2018, In: The Lancet. Global health. 6, 5, p. e494 1 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  File
  43 Downloads (Pure)

• Pharmacodynamic activity of DS003, a novel gp120 blocker, when administered to women as a vaginal tablet

  Nuttall, J., Arien, K., Michiels, J., Krit, M., Vanham, G., van Tilburg, P., du Puy, L., van Niekerk, N. & Nel, A., 2018, In: AIDS Research and Human Retroviruses. 34, p. 341-341 1 p.

  Research output: Contribution to journal › Conference abstract in journal

• Zika virus IgG in infants with microcephaly, Guinea-Bissau, 2016

  Rosenstierne, M. W., Schaltz-Buchholzer, F., Bruzadelli, F., Có, A., Cardoso, P., Jørgensen, C. S., Michiels, J., Heyndrickx, L., Ariën, K. K., Fischer, T. K. & Fomsgaard, A., 2018, In: Emerging Infectious Diseases. 24, 5, p. 948-950 3 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Guinea-Bissau 100%
  • Zika Virus 85%
  • Microcephaly 76%
  • Immunoglobulin G 47%
  • RNA 21%
  5 Downloads (Pure)
• 2017

  Can a ZIKA IGM and IGG immunoblot replace the virus neutralisation test to confirm screening test results?

  Van den Bossche, D., Foque, N., Michiels, J., Ariën, K. K. & Van Esbroeck, M., 2017, In: Tropical Medicine and International Health. 22, p. 122-122 1 p.

  Research output: Contribution to journal › Conference abstract in journal

• 2016

  2,6-Di(arylamino)-3-fluoropyridine derivatives as HIV non-nucleoside reverse transcriptase inhibitors

  Sergeyev, S., Yadav, A. K., Franck, P., Michiels, J., Lewi, P., Heeres, J., Vanham, G., Ariën, K. K., Vande Velde, C. M. L., De Winter, H. & Maes, B. U. W., 2016, In: Journal of Medicinal Chemistry. 59, 5, p. 1854-1868

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Reverse Transcriptase Inhibitors 100%
  • 5-fluoropyrimidine 80%
  • Fluorobenzenes 76%
  • Amination 68%
  • Pyrimidines 59%

• CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge

  Ariën, K. K., Baleux, F., Desjardins, D., Porrot, F., Coïc, Y-M., Michiels, J., Bouchemal, K., Bonnaffé, D., Bruel, T., Schwartz, O., Le Grand, R., Vanham, G., Dereuddre-Bosquet, N. & Lortat-Jacob, H., 2016, In: Scientific Reports. 6, 13 p., 34829.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Macaca 100%
  • HIV-1 78%
  • Binding Sites 69%
  • Cellulose 54%
  • Anti-Infective Agents 46%
  342 Downloads (Pure)

• Inhibition of HIV virus by neutralizing Vhh attached to dual functional liposomes encapsulating dapivirine

  Wang, S. X., Michiels, J., Ariën, K. K., New, R., Vanham, G. & Roitt, I., 2016, In: Nanoscale Research Letters. 11, p. 350

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Dapivirine 100%
  • Liposomes 88%
  • encapsulating 72%
  • Antibodies 67%
  • antibodies 63%
  22 Downloads (Pure)

• Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398

  Ariën, K. K., Venkatraj, M., Michiels, J., Joossens, J., Vereecken, K., Van der Veken, P., Heeres, J., De Winter, H., Heyndrickx, L., Augustyns, K. & Vanham, G., 2016, In: Journal of Antimicrobial Chemotherapy. 71, 5, p. 1159-1168

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  • Anti-Infective Agents 100%
  • HIV 67%
  • Dapivirine 36%
  • Mutation 32%
  • Rilpivirine 32%

• Specificity of Zika virus ELISA: interference with malaria [letter]

  Van Esbroeck, M., Meersman, K., Michiels, J., Ariën, K. K. & Van den Bossche, D., 2016, In: Eurosurveillance. 21, 21, 2 p., pii=30237.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  File
  44 Downloads (Pure)
• 2015

  A cross-sectional analysis of selected genital tract immunological markers and molecular vaginal microbiota in Sub-Saharan African women with relevance to HIV risk and prevention

  Kyongo Karanja, J., Crucitti, T., Menten, J., Hardy, L., Cools, P., Michiels, J., Delany-Moretlwe, S., Mwaura, M., Ndayisaba, G., Joseph, S., Fichorova, R., van de Wijgert, J., Vanham, G., Ariën, K. K. & Jespers, V., 2015, In: Clinical and Vaccine Immunology. 22, 5, p. 526-538

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Microbiota 100%
  • Interleukin-1 97%
  • Bacterial Vaginosis 94%
  • Genitalia 90%
  • HIV 67%
  135 Downloads (Pure)
• 2014

  Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398

  Grammen, C., Van den Mooter, G., Appeltans, B., Michiels, J., Crucitti, T., Ariën, K., Augustyns, K., Augustijns, P. & Brouwers, J., 2014, In: International Journal of Pharmaceutics. 475, 1-2, p. 238-244 7 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • polyethylene glycol 400 100%
  • Hypromellose Derivatives 91%
  • Anti-Infective Agents 68%
  • Gels 54%
  • HIV 46%

• From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds

  Venkatraj, M., Ariën, K., Heeres, J., Joossens, J., Dirié, B., Lyssens, S., Michiels, J., Cos, P., Lewi, P. J., Vanham, G., Maes, L., Van der Veken, P. & Augustyns, K., 2014, In: Bioorganic and Medicinal Chemistry. 22, 19, p. 5241-5248 8 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Triazines 100%
  • Reverse Transcriptase Inhibitors 77%
  • Viruses 75%
  • HIV 44%
  • Nucleoside Transport Proteins 32%
  1 Downloads (Pure)
• 2013

  Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission

  Ariën, K. K., Venkatraj, M., Michiels, J., Joossens, J., Vereecken, K., Van der Veken, P., Abdellati, S., Cuylaerts, V., Crucitti, T., Heyndrickx, L., Heeres, J., Augustyns, K., Lewi, P. J. & Vanham, G., 2013, In: Journal of Antimicrobial Chemotherapy. 68, 9, p. 2038-2047 10 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Dapivirine 100%
  • Pre-Exposure Prophylaxis 79%
  • Reverse Transcriptase Inhibitors 65%
  • HIV 37%
  • Anti-Infective Agents 36%

• Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with the HIV-1 surface protein

  Morellato-Castillo, L., Acharya, P., Combes, O., Michiels, J., Descours, A., Ramos, O. H., Yang, Y., Vanham, G., Ariën, K. K., Kwong, P. D., Martin, L. & Kessler, P., 2013, In: J Med Chem. 56, 12, p. 5033-5047 15 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • HIV-1 100%
  • Membrane Proteins 95%
  • 4-aminophenylalanine 64%
  • Phenylalanine 63%
  • Cyclohexane 44%

• In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine

  das Neves, J., Araujo, F., Andrade, F., Michiels, J., Ariën, K. K., Vanham, G., Amiji, M., Bahia, M. F. & Sarmento, B., 2013, In: Molecular Pharmaceutics. 10, 7, p. 2793-2807 15 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Dapivirine 100%
  • Anti-HIV Agents 74%
  • Nanoparticles 48%
  • 1-bromohexadecane 24%
  • In Vitro Techniques 23%
• 2012

  MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency

  Grupping, K., Selhorst, P., Michiels, J., Vereecken, K., Heyndrickx, L., Kessler, P., Vanham, G., Martin, L. & Ariën, K. K., 2012, In: Retrovirology. 9, 36, p. 1-16 16 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • HIV-1 100%
  • Binding Sites 88%
  • Mutation 64%
  • Proteins 42%
  • Viruses 28%
  19 Downloads (Pure)

• Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine

  das Neves, J., Michiels, J., Ariën, K. K., Vanham, G., Amiji, M., Bahia, M. F. & Sarmento, B., 2012, In: Pharmaceutical Research. 29, 6, p. 1468-1484 17 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Dapivirine 100%
  • Cytotoxicity 80%
  • Anti-Infective Agents 55%
  • Nanoparticles 54%
  • caprolactone 38%

• Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women

  Kyongo, J. K., Jespers, V., Goovaerts, O., Michiels, J., Menten, J., Fichorova, R. N., Crucitti, T., Vanham, G. & Ariën, K. K., 2012, In: PLoS ONE. 7, 8, p. e43951

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  Open Access

  File

  • Female Genitalia 100%
  • Anti-Infective Agents 64%
  • Biomarkers 55%
  • Menstrual Cycle 44%
  • Chemokines 39%
  8 Downloads (Pure)

• Synthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents

  Venkatraj, M., Ariën, K. K., Heeres, J., Joossens, J., Messagie, J., Michiels, J., Van der Veken, P., Vanham, G., Lewi, P. J. & Augustyns, K., 2012, In: Bioorganic and Medicinal Chemistry Letters. 22, 23, p. 7174-7178 5 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Triazines 100%
  • Dimers 96%
  • Structure-Activity Relationship 75%
  • Antiviral Agents 55%
  • HIV-1 27%
• 2011

  Human Immunodeficiency Virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides

  Selhorst, P., Vazquez, AC., Terrazas-Aranda, K., Michiels, J., Vereecken, K., Heyndrickx, L., Weber, J., Quiñones-Mateu, ME., Ariën, KK. & Vanham, G., 2011, In: Antimicrobial Agents and Chemotherapy. 55, 4, p. 1403-1413 11 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  File

  • Reverse Transcriptase Inhibitors 100%
  • MIV-160 91%
  • Anti-Infective Agents 85%
  • HIV-1 71%
  • UC 781 53%
  8 Downloads (Pure)

• Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) [letter]

  Venkatraj, M., Ariën, KK., Heeres, J., Dirié, B., Joossens, J., Van Goethem, S., Van der Veken, P., Michiels, J., Vande Velde, CML., Vanham, G., Lewi, PJ. & Augustyns, K., 2011, In: Bioorganic and Medicinal Chemistry. 19, 20, p. 5924-5934 11 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

  • Human immunodeficiency virus 1 reverse transcriptase 100%
  • Reverse Transcriptase Inhibitors 88%
  • HIV-1 63%
• 2008

  CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides

  Van Herrewege, Y., Morellato, L., Descours, A., Aerts, L., Michiels, J., Heyndrickx, L., Martin, L. & Vanham, G., 2008, In: Journal of Antimicrobial Chemotherapy. 61, 4, p. 818-826 9 p.

  Research output: Contribution to journal › A1: Web of Science-article › peer-review
• 2007

  A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides

  Van Herrewege, Y., Michiels, J., Waeytens, A., De Boeck, G., Salden, E., Heyndrickx, L., van den Mooter, G., de Béthune, MP., Andries, K., Lewi, P., Praet, M. & Vanham, G., 2007, In: Antiviral Research. 74, 2, p. 111-124

  Research output: Contribution to journal › A1: Web of Science-article › peer-review
• 2004

  A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides

  Van Herrewege, Y., Vanham, G., Michiels, J., Fransen, K., Kestens, L., Andries, K., Janssen, P. & Lewi, P., 2004, In: Antimicrobial Agents and Chemotherapy. 48, 10, p. 3684-3689

  Research output: Contribution to journal › A1: Web of Science-article › peer-review

• In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides

  Van Herrewege, Y., Michiels, J., Van Roey, J., Fransen, K., Kestens, L., Balzarini, J., Lewi, P., Vanham, G. & Janssen, P., 2004, In: Antimicrobial Agents and Chemotherapy. 48, 1, p. 337-339

  Research output: Contribution to journal › A1: Web of Science-article › peer-review
• 1995

  Cyclospora sp.: a coccidian that causes diarrhoea in travellers

  Lontie, M., Degroote, K., Michiels, J., Bellers, J., Mangelschots, E. & Vandepitte, J., 1995, In: Acta Clinica Belgica. 50, p. 288-290

  Research output: Contribution to journal › A1: Web of Science-article › peer-review